Yusuke Oji

8.7k total citations
112 papers, 4.2k citations indexed

About

Yusuke Oji is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Yusuke Oji has authored 112 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Molecular Biology, 27 papers in Oncology and 27 papers in Immunology. Recurrent topics in Yusuke Oji's work include Renal and related cancers (87 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (21 papers). Yusuke Oji is often cited by papers focused on Renal and related cancers (87 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (21 papers). Yusuke Oji collaborates with scholars based in Japan, Australia and United States. Yusuke Oji's co-authors include Haruo Sugiyama, Yoshitaka Oka, Akihiro Tsuboi, Naoki Hosen, Hiroya Tamaki, Manabu Kawakami, Sumiyuki Nishida, Toshihiro Soma, Toyoshi Tatekawa and Ichiro Kawase and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Yusuke Oji

108 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yusuke Oji Japan	33	3.0k	1.3k	1.2k	1000	885	112	4.2k
Akihiro Tsuboi Japan	32	2.3k 0.8×	1.0k 0.8×	1.0k 0.9×	638 0.6×	658 0.7×	96	3.2k
Naoki Hosen Japan	28	1.7k 0.6×	791 0.6×	871 0.7×	659 0.7×	362 0.4×	111	2.9k
Mårina Lafage‐Pochitaloff France	29	1.4k 0.5×	723 0.6×	873 0.7×	2.2k 2.2×	1.1k 1.2×	76	3.7k
Susan Mathew United States	24	1.1k 0.4×	785 0.6×	284 0.2×	1.0k 1.0×	999 1.1×	100	3.3k
Nobuo Maseki Japan	31	2.2k 0.7×	833 0.7×	463 0.4×	1.9k 1.9×	685 0.8×	90	4.0k
Camille N. Abboud United States	27	810 0.3×	783 0.6×	558 0.5×	1.6k 1.6×	335 0.4×	109	2.7k
Jean‐Michel Cayuela France	33	1.0k 0.3×	784 0.6×	552 0.5×	2.1k 2.1×	1.4k 1.6×	101	3.8k
Harald Rieder Germany	31	1.1k 0.4×	1.2k 1.0×	224 0.2×	1.0k 1.0×	934 1.1×	84	3.5k
Abraham Avigdor Israel	32	969 0.3×	1.6k 1.3×	755 0.6×	1.4k 1.4×	400 0.5×	139	3.7k
Niels Pallisgaard Denmark	34	2.0k 0.7×	1.4k 1.1×	293 0.2×	2.3k 2.3×	896 1.0×	116	5.3k

Countries citing papers authored by Yusuke Oji

Since Specialization

Citations

This map shows the geographic impact of Yusuke Oji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuke Oji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuke Oji more than expected).

Fields of papers citing papers by Yusuke Oji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusuke Oji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuke Oji. The network helps show where Yusuke Oji may publish in the future.

Co-authorship network of co-authors of Yusuke Oji

This figure shows the co-authorship network connecting the top 25 collaborators of Yusuke Oji. A scholar is included among the top collaborators of Yusuke Oji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuke Oji. Yusuke Oji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujiki, Fumihiro, Soyoko Morimoto, Kento Inoue, et al.. (2023). Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs. Cancer Immunology Immunotherapy. 72(7). 2347–2356. 1 indexed citations

Fujiki, Fumihiro, Soyoko Morimoto, Ayako Isotani, et al.. (2022). T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy. Frontiers in Immunology. 13. 935465–935465. 8 indexed citations

Nakata, Jun, Kayako Isohashi, Yoshitaka Oka, et al.. (2021). Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics. 11(6). 1041–1041. 7 indexed citations

Fujiki, Fumihiro, Akihiro Tsuboi, Soyoko Morimoto, et al.. (2020). Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunology Immunotherapy. 70(1). 253–263. 7 indexed citations

Hashii, Yoshiko, Yoshitaka Oka, Naoki Kagawa, et al.. (2020). Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review. Frontiers in Oncology. 10. 1188–1188. 3 indexed citations

Tsuboi, Akihiro, Naoya Hashimoto, Fumihiro Fujiki, et al.. (2018). A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology Immunotherapy. 68(2). 331–340. 43 indexed citations

Oka, Yoshitaka, Akihiro Tsuboi, Jun Nakata, et al.. (2017). Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy. Oncology Research and Treatment. 40(11). 682–690. 30 indexed citations

Hashimoto, Naoya, Akihiro Tsuboi, Naoki Kagawa, et al.. (2015). Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunology Immunotherapy. 64(6). 707–716. 34 indexed citations

Ohta, Tsuyoshi, Yusuke Oji, Haruo Sugiyama, et al.. (2014). The Wilms' Tumor Gene WT1 − 17AA/− KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model. Translational Oncology. 7(5). 580–589. 10 indexed citations

10.

Hosen, Naoki, Tetsuo Maeda, Yoshiko Hashii, et al.. (2014). Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects. Expert Review of Hematology. 7(5). 671–681. 4 indexed citations

11.

Oue, Takaharu, Shuichiro Uehara, Hiroaki Yamanaka, et al.. (2011). Expression of Wilms tumor 1 gene in a variety of pediatric tumors. Journal of Pediatric Surgery. 46(12). 2233–2238. 16 indexed citations

12.

Ichinohasama, Ryo, Yusuke Oji, Hisayuki Yokoyama, et al.. (2010). Sensitive immunohistochemical detection of WT1 protein in tumors with anti‐WT1 antibody against WT1 235 peptide. Cancer Science. 101(5). 1089–1092. 4 indexed citations

13.

Oka, Yoshitaka, Akihiro Tsuboi, Fumihiro Fujiki, et al.. (2009). WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide. Anti-Cancer Agents in Medicinal Chemistry. 9(7). 787–797. 17 indexed citations

14.

Kawakami, Manabu, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2009). Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8⁺ T cells in patients with myeloid malignancies. Cancer Science. 101(3). 594–600. 14 indexed citations

15.

Oka, Yoshitaka, Akihiro Tsuboi, Yusuke Oji, Ichiro Kawase, & Haruo Sugiyama. (2008). WT1 peptide vaccine for the treatment of cancer. Current Opinion in Immunology. 20(2). 211–220. 90 indexed citations

16.

Kawakami, Manabu, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2007). Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5 μg/Body) in a Patient with Chronic Myelomonocytic Leukemia. International Journal of Hematology. 85(5). 426–429. 29 indexed citations

17.

Jomgeow, Tanyarat, Yusuke Oji, Yoko Ikeda, et al.. (2006). Wilms’ tumor gene WT1 17AA(–)/KTS(–) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Science. 97(4). 259–270. 57 indexed citations

18.

Nakatsuka, Shin‐ichi, Yusuke Oji, Tetsuya Horiuchi, et al.. (2006). Immunohistochemical detection of WT1 protein in a variety of cancer cells. Modern Pathology. 19(6). 804–814. 229 indexed citations

19.

Oji, Yusuke, Hidenori Inohara, Mitsuhiro Nakazawa, et al.. (2003). Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Science. 94(6). 523–529. 47 indexed citations

20.

Oka, Yoshitaka, Akihiro Tsuboi, Masaki Murakami, et al.. (2003). Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. International Journal of Hematology. 78(1). 56–61. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact